InvestorLens

TECH — BIO-TECHNE CORP

Public company

Sign in to save5 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying TECH?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
83
Institutional Conviction
Net accumulation · 5 buying vs 1 selling last quarter
65
Macro Tailwind
Macro conditions are mixed for this sector
56
Congressional Activity
0 congressional purchases, 1 sale disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 6 tracked investors who changed their TECH position last quarter, 5 bought and 1 sold (83% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime). 0 congressional purchases, 1 sale disclosed in the last 6 months.

Supporting evidence
  • +5 tracked investors added or increased positions last quarter (Izzy Englander, George Soros, Paul Tudor Jones, …)
  • +5 tracked investors reported holding TECH at their latest filing
  • +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
  • −Congressional disclosures lean toward selling (1 sales vs 0 purchases, 6 months)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About BIO-TECHNE CORP (TECH)

BIO-TECHNE CORP (TECH) appears in the most recent 13F filings of 5 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $132M. Across recent filings, tracked investors recorded 14 new positions, 6 increased, 5 reduced, and 10 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in TECH

57
/100
Mixed Activity
Added / Increased20
Reduced5
Exited10
BearishBullish
Crowded Trade Score™

How many top investors track TECH

33
/100
Emerging Interest
5investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

TECH Ownership Composition

How BIO-TECHNE CORP is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
59% of tracked value
Institutions
5
tracked investors
Total Reported
$259.9M
combined 13F value
Types2
  • Multi-Strategy / Quant59.1%
  • Macro40.9%
Multi-Strategy / Quant(2)
59.1%
Macro(3)
40.9%

Tracked investors currently reporting TECH

1 tracked investor has since exited this position — listed separately below.

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    1.1M
    Value
    $74.2M
    % Portfolio
    0.01%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    1.1M
    Value
    $79.3M
    % Portfolio
    0.03%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    943.3K
    Value
    $66.6M
    % Portfolio
    0.09%
  • George SorosJun 30, 2026
    Soros Fund Management
    Shares
    535.4K
    Value
    $37.8M
    % Portfolio
    0.46%
  • Ray DalioJun 30, 2026
    Bridgewater Associates
    Shares
    26.8K
    Value
    $1.9M
    % Portfolio
    0.01%

Previously held TECH

These investors reported TECH in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Steve CohenPoint72 Asset Management295K$15.4MMar 31, 2026

Recent activity

Frequently asked questions

How many institutional investors hold TECH?
5 tracked institutional investors disclosed a position in TECH (BIO-TECHNE CORP) in their most recent 13F filing.
Who is the largest institutional holder of TECH?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in TECH, valued at $132M.
Did institutional ownership of TECH increase or decrease?
Across recent 13F filings, tracked investors recorded 14 new positions, 6 increased, 5 reduced, and 10 fully exited TECH.
Where does this TECH ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.